Similarly, Baicalin (BA) exhibits promise in reducing NLRP3 and GSDMD expression levels, as well as the secretion of IL-1β and IL-18, through modulation of the NRF2/HO-1/NRLP3 pathway, thereby alleviating pyroptosis in hepatic cells of NASH patients (Shi et al., 2020; Shi et al., 2022). This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.